Company profile
Sphere Fluidics Limited
Automated high-throughput single cell analysis platforms based on microfluidic picodroplet technology
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
CS01 | Transaction MzQ1NjI4NjQ4NWFkaXF6a2N4
Published 25 Feb 2025 06:37
Last confirmation statement made up date
CERTNM | Transaction MzQ1NTgyMzg1NGFkaXF6a2N4
Published 20 Feb 2025 01:11
RESOLUTIONS | Transaction WURDVUZPMUthZGlxemtjeA | Paper/PDF filed
Published 08 Oct 2024 06:28
SH01 | Transaction MzQzNzk4NTk5M2FkaXF6a2N4
Published 01 Oct 2024 03:49
RESOLUTIONS | Transaction WURCSEpUWlZhZGlxemtjeA | Paper/PDF filed
Published 18 Sep 2024 07:11
AP01 | Transaction MzQzNTA3NjYwMGFkaXF6a2N4
Published 10 Sep 2024 10:32
Last accounts made up date
Company registered at Companies House
Sphere Bio develops microfluidic cell and molecule screening technology with applications in cellular research, biopharmaceutical production, and diagnostics.
Sphere Fluidics develops microfluidic cell and molecule screening technology with applications in cellular research, biopharmaceutical production, and diagnostics.
Sphere Fluidics Limited is an established Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative Research and Development services in this area.
Sphere Fluidics is one of the very few teams in the world with expertise in single cell analysis and pico droplet technology. The company has leading-edge, patented technology and proprietary know-how enables analysis and detection of single cells and their biomolecules. Sphere Fluidics has extensive management experience in successfully commercialising innovative science and engineering. Its expertise in new science with key applications has particular impact for novel biopharmaceutical and biosimilar discovery. Sphere Fluidics' novel process for single cell analysis and characterisation provides significant saving of time, resource and money compared to conventional workflows.
25 Jan 2024 to 25 Jan 2026
To embed expertise in injection moulding for rapid prototyping of hard plastic microfluidics; expanding in-house manufacturing capabilities to produce plastic biochips, thereby, bringing products to market faster, at lower cost and higher quality than competitors.
1 Mar 2023 to 31 Aug 2023
Sphere Fluidics Limited is an established Life Sciences company based in Cambridge, UK. We provide tools for biopharmaceutical organisations which include instruments and cartridges based on novel microfluidics. This project addresses the speed and efficiency of a critical quality control test which is required to validate the Cyto-Mine single cell analys...
1 Jan 2023 to 31 Dec 2026
no public description
1 Jul 2020 to 30 Jun 2022
To develop a commercial instrument (PISCES-2) to allow high-throughput, monodisperse microdroplet generation.
1 Oct 2017 to 30 Apr 2020
Awaiting Public Project Summary
1 Jul 2017 to 31 Oct 2020
Genetic engineering (GE) is an established tool for R&D and promises to become a globally used approach to correct and treat important diseases, such as cancer and genetic disease, and also able to tackle and solve important environmental issues. Current approaches are dependent upon manual labour and extensive screening, and are highly inefficient and ti...
1 Oct 2015 to 30 Sep 2018
Cell therapy promises to become a globally used approach to treat important diseases, such as cancer. Current regimes can involve removing a patient's white blood cells (e.g. T-cells), reprogramming them to fight cancer and then reintroducing them to the patient. Current cellular reprogramming techniques are very inefficient (e.g. as low as 3%) and involv...
1 Oct 2014 to 31 Mar 2016
Synthetic biology has advanced genetic manipulation by applying engineering principles (Design-Build-Test) to enable new discoveries by modifying safe microbes with custom DNA. The ability to write DNA has accelerated, but synthetic biology is now limited by a lack of high-throughput measurement methods to assess performance of custom-built strains. The p...
1 Jun 2014 to 30 Nov 2015
Sphere Fluidics Limited is an SME focusing on the development of novel, single cell analysis technologies. MedImmune, the global biopharmaceuticals arm of AstraZeneca, is a pioneer in biopharmaceutical discovery and development. Both companies have pooled their synergistic, science skills to propose the development of a unique, integrated microfluidic ins...
